[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355703-105":59,"doc-detail-355703-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","precision-medicine-clinic-molecular-tumor-board-comprehensive-molecular-analyses-for-diagnosis-and-treatment-guidance-in-an-adult-neuroblastoma-patient","Precision Medicine Clinic - Molecular Tumor Board - Comprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient","","Metastatic cancers of unknown primary (CUP) present major diagnostic and therapeutic challenges. The article reports a case of a 63-year-old male with CUP exhibiting neuroendocrine differentiation and metastases to bone, bone marrow, supraclavicular and retroperitoneal lymph nodes. Immunohistochemistry and molecular profiling showed strong pan-neurotrophic Trk expression without NTRK gene fusion. Whole-genome methylation profiling suggested neuroblastoma but fell below diagnostic thresholds; imaging and lab data supported INRGSS stage M disease. After multimodal therapy and precision oncology guidance via molecular tumor board, multiple targeted and immunotherapeutic options were tried, yet progression occurred, highlighting unmet needs for elderly patients with neuroblastoma.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/precision-medicine-clinic-molecular-tumor-board-comprehensive-molecular-analyses-for-diagnosis-and-treatment-guidance-in-an-adult-neuroblastoma-patient/355703/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/precision-medicine-clinic-molecular-tumor-board-comprehensive-molecular-analyses-for-diagnosis-and-treatment-guidance-in-an-adult-neuroblastoma-patient/355703.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What diagnostic signal was observed regarding Trk expression in this CUP case?","Question",{"text":112,"@type":113},"Strong pan-neurotrophic Trk expression was detected, but without NTRK gene fusion, supporting a neural cell origin.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did methylation profiling contribute to the diagnostic process?",{"text":117,"@type":113},"Genome-wide methylation profiling suggested neuroblastoma, but the results were below diagnostic thresholds, requiring confirmation through subsequent imaging and laboratory findings.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment approaches were selected after molecular tumor board discussion?",{"text":121,"@type":113},"The molecular tumor board identified potential targets, leading to therapies including dinutuximab beta, nivolumab, cabozantinib, I-131-mIBG radionuclide therapy, and alpelisib.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355703,1790485727,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","The Oncologist, 2026, 31, oyag132  \n[https://doi.org/10.1093/oncolo/oyag132](https://doi.org/10.1093/oncolo/oyag132)  \n[Published: April 6](Published: April 6), 2026  \nPrecision Medicine Clinic: Molecular Tumor Board  \nComprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient  \nDamian T. Rieke1,2,3,4,*, , Stefan Schwartz1,3, Sebastian Ochsenreither1,2,3,4, Bj€orn Chapuy1,3,4,  \nHolger Amthauer4,5, Hedwig E. Deubzer1,4,6,7, , Annika Lehmann8, Ulrich Keilholz1,2,4, Eva Wardelmann9, Christian Vokuhl10, Angelika Eggert1,4,6, Stefan Fr€ohling11,12, David Horst1,8, David Capper1, 13, ,  \nUlrich Keller1,3,4,14,15, , Mihnea P. Dragomir1,8,‡, Simon Schallenberg1,7,‡,*,   \n1German Cancer Consortium (DKTK), Partner Site Berlin, a Partnership between DKFZ and Charit - Universit€atsmedizin Berlin, Berlin 10117, Germany 2Charite Comprehensive Cancer Center, Charit-Universit€atsmedizin Berlin, Corporate Member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 10117, Germany  \n3 Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charit-Universit€atsmedizin Berlin, Corporate Member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 12203, Germany  \n4 National Center for Tumor Diseases (NCT), NCT Berlin, a Partnership between DKFZ, Charit Universit€atsmedizin, BIH and MDC, Berlin 10117, Germany 5 Department of Nuclear Medicine, Charit - Universit€atsmedizin Berlin, Corporate Member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 13353, Germany  \n6 Department of Pediatric Oncology and Hematology, Campus Virchow Klinikum, Charit-Universit€atsmedizin Berlin, Corporate Member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 13353, Germany  \n7 Berlin Institute of Health at Charit – Universit€atsmedizin Berlin, Berlin 10117, Germany  \n8 Institute of Pathology, Charit-Universit€atsmedizin Berlin, Corporate Member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 10117, Germany  \n9Gerhard-Domagk-Institut f€ur Pathologie, Universit€atsklinikum M€unster, M€unster 48149, Germany  \n10 Department of Pathology, Section of Pediatric Pathology, University of Bonn, Bonn 53127, Germany  \n11 Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany  \n12 National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership between DKFZ and Heidelberg University Hospital, Heidelberg 69120, Germany 13 Department of Neuropathology, Charit-Universit€atsmedizin Berlin, Corporate Member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 10117, Germany  \n14 Max-Delbr€uck-Center for Molecular Medicine, Berlin 13125, Germany  \n15Cluster of Excellence ImmunoPreCept, Charit - Universit€atsmedizin Berlin, Berlin 12203, Germany  \n*Corresponding authors. Damian T. Rieke. E-mail: [damian.rieke@charite.de](damian.rieke@charite.de); Simon Schallenberg. E-mail: [simon.schallenberg@charite.de](simon.schallenberg@charite.de)[ ](simon.schallenberg@charite.de)‡ Mihnea P. Dragomir and Simon Schallenberg: Equal contribution.  \nAbstract  \nMetastatic cancers of unknown primary (CUP) pose significant diagnostic and therapeutic challenges. We present the case of a 63-year old male patient with a CUP showing neuroendocrine differentiation, metastasized to the iliac bone, bone marrow, supraclavicular and retroperitoneal lymph nodes. Immunohistochemical and molecular profiling revealed strong pan-neurotrophic tyrosine kinase (Trk) expression without NTRK-gene fusion, corroborating the neural cell origin. Following molecular tumor board (MTB) discussion, genome-wide methylation profiling suggested the diagnosis of a neuroblastoma but results were below diagnostic thresholds. Subsequent imaging and laboratory findings confirmed an INRGSS stage M neuroblastoma, a rare finding in older adults. Despite multimodal therapy, including po","cbCaib08ZVUBZFPk","https://ap.wps.com/l/cbCaib08ZVUBZFPk","pdf",1377870,"English","# Abstract\n## Case description and diagnostic findings\n## Molecular tumor board discussion\n## Treatment course and outcomes\n## Key points","[{\"question\":\"What diagnostic signal was observed regarding Trk expression in this CUP case?\",\"answer\":\"Strong pan-neurotrophic Trk expression was detected, but without NTRK gene fusion, supporting a neural cell origin.\"},{\"question\":\"How did methylation profiling contribute to the diagnostic process?\",\"answer\":\"Genome-wide methylation profiling suggested neuroblastoma, but the results were below diagnostic thresholds, requiring confirmation through subsequent imaging and laboratory findings.\"},{\"question\":\"What treatment approaches were selected after molecular tumor board discussion?\",\"answer\":\"The molecular tumor board identified potential targets, leading to therapies including dinutuximab beta, nivolumab, cabozantinib, I-131-mIBG radionuclide therapy, and alpelisib.\"}]","Precision Medicine Clinic - Molecular Tumor Board - Comprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient | PDF",1790120564,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a82bca37a60aaf78bbbab533452efc0.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f067e928583e1472f958a9a9b10cbe1.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62b0e3872f3ecc01ae3a201f3aa43877.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/930eb2480daa178e95b81781f365bb50.webp",980,1287]